Related Experiment Video
Updated: May 14, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis
Yuta Nanjo1, Yoshikazu Ishii, Soichiro Kimura
1Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo, 143-8540, Japan.
Abstract:
Lipopolysaccharide (LPS) is a major contributing factor to endotoxic shock. Colistin specifically binds to LPS. However, it has the disadvantages that adverse reactions are common and it has a short half-life. To overcome these disadvantages, we prepared slow-releasing colistin microspheres and examined the efficacy of these colistin microspheres in a mouse model of endotoxin-induced sepsis. We prepared the colistin microspheres using poly-lactic-co-glycolic acid. For acute toxicity investigations, mice were overdosed with colistin sulfate or colistin microspheres. The group administered with colistin microspheres was associated with less acute toxicity and fewer nephrotoxic changes on histopathological examination compared to the group administered with colistin sulfate alone. For pharmacokinetic analysis, mice were subcutaneously administered with colistin microspheres or colistin sulfate alone. The plasma concentration of colistin was higher in the colistin microspheres group than in the colistin sulfate group at 12 and 24 h after administration. Moreover, mice were intraperitoneally injected with LPS and then immediately subcutaneously administered with blank microspheres, colistin microspheres or colistin sulfate alone. The levels of endotoxin in the sera and cytokine in the spleens were then measured. A significant reduction in the serum endotoxin level in the colistin microspheres group was observed at 24 h. The reduced endotoxin levels in the sera were correlated with the lower cytokine levels in the spleens of mice treated with colistin microspheres. Our results suggest that the use of colistin microspheres may help to maintain a higher colistin concentration in blood, reduce the levels of endotoxin and cytokines in endotoxin-induced sepsis, and lead to decreased toxicity.
Insights
Slow-releasing colistin microspheres reduce toxicity and improve efficacy in endotoxin-induced sepsis models. These microspheres maintain higher colistin concentrations, lower endotoxin and cytokine levels, and decrease adverse reactions compared to standard colistin sulfate.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Toxicology
Background:
- Lipopolysaccharide (LPS) is a primary cause of endotoxic shock.
- Colistin effectively binds LPS but has limitations including adverse reactions and a short half-life.
- Developing improved colistin formulations is crucial for managing sepsis.
Purpose of the Study:
- To develop and evaluate slow-releasing colistin microspheres for treating endotoxin-induced sepsis.
- To assess the toxicity, pharmacokinetics, and efficacy of colistin microspheres compared to colistin sulfate.
Main Methods:
- Colistin microspheres were prepared using poly-lactic-co-glycolic acid.
- Acute toxicity and nephrotoxicity were assessed in mice.
- Pharmacokinetic analysis was performed after subcutaneous administration.
- Efficacy was evaluated in a mouse model of LPS-induced sepsis by measuring serum endotoxin and spleen cytokine levels.
Main Results:
- Colistin microspheres demonstrated reduced acute toxicity and nephrotoxicity compared to colistin sulfate.
- Higher plasma colistin concentrations were observed at 12 and 24 hours post-administration for microspheres.
- Colistin microspheres significantly reduced serum endotoxin levels at 24 hours.
- Reduced endotoxin levels correlated with lower spleen cytokine levels, indicating reduced inflammation.
Conclusions:
- Slow-releasing colistin microspheres offer a promising alternative to colistin sulfate for sepsis treatment.
- This formulation enhances colistin's pharmacokinetic profile and reduces associated toxicity.
- Colistin microspheres effectively mitigate endotoxin and cytokine storm in endotoxin-induced sepsis.

